Alan W. Partin, MD, Johns Hopkins Medical Institutions, Baltimore, Maryland, discusses which non-genomic biomarkers are the most useful for monitoring patients after initial treatment.
Interview produced by Prostatepedia
Keywords: non-genomic biomarkers, PSA test, prostate cancer